Online on 12 August the editorial written by Eleni Armeni, Antonio Cano, Margaret Rees and Irene Lambrinoudaki after publication of 20 year WHI follow up data concludes that that estrogen monotherapy is safe in the long-term with regard to breast cancer risk. The need to use progestogens with a better breast safety profile, such as micronized progesterone or dydrogesterone becomes even more evident.
Click here to read more.